Ulcerative Colitis Clinical Trial
Official title:
Counseling to Optimize Medication Adherence in Expectant Mothers With Inflammatory Bowel Disease (COACH-IBD)
Inflammatory Bowel Disease (IBD) is a chronic inflammatory disorder of the gastrointestinal
tract that comprises two subtypes, Crohn's disease (CD) and Ulcerative Colitis (UC). Because
the risk of IBD is greatest during the third decade of life, its impact for women is during
the reproductive years. Women with inflammatory bowel disease are at a 2-fold higher risk of
adverse outcomes during pregnancy as compared to the general population. Pregnancy is an
especially vulnerable time for women with IBD, and out of misguided concerns that medications
may confer unnecessary harms to their fetus, many women often stop taking life savings
medications; without realizing that this sub-optimal adherence could actually lead to life
threatening complications for them and their fetus. Counseling pregnant women with IBD is
therefore an important step in improving medication adherence. The investigators hypothesize
that counseling sessions with an IBD nurse that incorporates motivational interviewing and
telemedicine-based follow-up sessions tailored to individual needs will improve medication
adherence and pregnancy outcomes.
The following specific aims are to be addressed by this multi-center randomized clinical
trial comparing individual nurse-based counseling to standard of care:
Specific Aim #1: To assess whether patient-centered counseling incorporating motivational
interviewing and telemedicine-based follow-up by an IBD nurse leads to improved medication
adherence during pregnancy and pregnancy outcomes
Specific Aim #2: To validate the use of self-reported medication adherence during pregnancy
in the IBD population
IBD and Pregnancy: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the
gastrointestinal tract that comprises two subtypes, Crohn's disease (CD) and Ulcerative
Colitis (UC), Canada has among the highest reported incidence of CD and UC in the world, as
high as 20.2 and 19.5 per 100,000, respectively. Because the risk of IBD is greatest during
the third decade of life, its greatest impact for women in during the reproductive years. In
comparison to the general population, women with IBD have a significantly higher risk of
pregnancy related complications.
IBD Disease Activity and Outcomes: Active IBD symptoms during pregnancy significantly
increase the risk of preterm birth. Furthermore, women with IBD who suffer a relapse during
pregnancy, requiring hospitalization, are more likely than their asymptomatic counterparts to
delivery preterm birth and low birth weight newborns. More than two-thirds of women who have
active disease at the time of conception will have continued or worsened symptoms during
pregnancy. In contrast, women who are asymptomatic at conception are half as likely to have
active disease during pregnancy. This data underscores the importance of achieving disease
remission prior to conception and aggressively treating relapses during pregnancy.
Medication Adherence During Pregnancy: Despite the safety of most IBD medications, most
pregnant women with IBD exhibit low medication adherence rates. Medication non-compliance is
often linked to concerns that IBD medication may confer unnecessary harm to the fetus. Most
women have reported that they would rather endure symptoms of IBD rather than confer risk to
the fetus, without realizing that active IBD itself is strongly associated with adverse
pregnancy outcomes. Consequently, most of these women decrease the dosage or stop their
medications without informing their treating physicians, thus comprising treatment.
Motivational Interviewing Adherence: Motivational Interviewing (MI) refers to a
patient-centered process in which a health care provider employs specific communication
skills and strategies that facilitate the patients confidence and decision making, while
emphasising respect for autonomy. A key feature of MI is that the counselling process induces
behavioural change by triggering and channelling a patient's internal motivations for change.
Previous clinical trials have demonstrated the effectiveness of MI in improving medication
adherence for various chronic condition, including diabetes, hypertension, obesity and HIV.
In a small study of IBD subjects, MI was associated with positive patient perceptions of the
physician-patient relationship. In another pilot study, nurse-administered MI in UC patients
was associated with medication adherence as high as 90%.
Rationale: Pregnancy is an especially vulnerable time for women with IBD. During this
critical window of time, even brief lapses in medication adherence can lead to sub optimal
control of IBD disease activity that can lead to life-threatening complications to both
mother and fetus. Adverse outcomes such as preterm delivery have long-term implications for
the children of mother with IBD. Out of misguided concerns for their fetus, many women may
stop lifesaving medications. Educating pregnant women with IBD is an important step in
improving adherence rates, but tools such as motivational interviewing have proven to be much
more powerful. As such the primary objective of this study is to assess, through a
multi-center clinical trial, whether patient-centered counselling incorporating motivational
interviewing and telemedicine-based follow-up by an IBD nurse leads to improved medication
adherence during pregnancy and improved pregnancy outcomes. The investigators hypothesize
that patient-centered counselling will result in higher medication adherence rates and
improved pregnancy outcomes.
Design: The investigators will conduct a multi-center randomized controlled clinical trial
that includes 3 University of Toronto affiliated hospitals (Mount Sinai Hospital, University
Health Network, and Women's College Hospital) and the University of Calgary.
Study Population: The investigators will enroll 220 pregnant women who have or will be seen
by: an obstetrician or maternal fetal specialist at Mount Sinai Hospital or the University of
Calgary; or a gastroenterologist at Mount Sinai Hospital, University Health Network, Women's
College, or the University of Calgary who meet the inclusion criteria.
Significance: This clinical intervention has the potential to directly impact inflammatory
bowel disease patients by reducing complications of the disease during pregnancy.
Motivational interviewing can potentially improve adherence and optimize the impact of IBD
medical therapies. Most tertiary centers already have clinical IBD nurses. The structured
training of an IBD nurse to counsel pregnant women through motivational interviewing is a
reproducible intervention and can be used at tertiary centers throughout the country. Because
poor disease control can lead to preterm delivery, which is associated with lifelong chronic
illnesses, patient-centered counselling would not only ameliorate the IBD health of mothers,
but also improve the lives of their children. Findings from this study would also allow
physicians to lobby provincial health ministries to request funds for IBD nurse counsellors.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |